View Older Stories View More Recent Stories

Jul 13, 2023 08:40AM Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Jul 6, 2023 08:45AM Moleculin to Participate in the Virtual Investor Summer Spotlight Series
Jun 13, 2023 08:35AM Moleculin to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
May 30, 2023 09:05AM Moleculin Announces Adjournment of 2023 Annual Meeting to June 15, 2023
May 11, 2023 07:05AM Moleculin Reports First Quarter 2023 Financial Results
May 10, 2023 04:05PM Moleculin Provides Update on Ongoing Clinical Trials and Outlines Expected Upcoming Milestones
May 4, 2023 08:35AM Moleculin to Report First Quarter Financial Results on May 11, 2023 and Host Conference Call and Webcast
May 2, 2023 08:35AM Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Apr 18, 2023 01:37PM Moleculin Biotech (MBRX) Presents Positive Pharmacokinetics and Tissue-Organ Distribution Data
Apr 18, 2023 01:35PM Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models
Mar 23, 2023 07:10AM Moleculin Biotech (MBRX) Reports FY22, Provides Pipeline Update
Mar 23, 2023 07:10AM Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update
Mar 22, 2023 04:21PM Moleculin (MBRX) Reports Interim Phase 2 Data in STS Trial
Mar 22, 2023 04:20PM Moleculin Announces Interim Phase 2 Data in STS Clinical Trial and Update on Recruiting, Preliminary Efficacy and Expected Milestones for AML Clinical Trials
Mar 21, 2023 08:50AM Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Mar 15, 2023 08:30AM Moleculin to Report Full Year 2022 Financial Results on March 22, 2023 and Host Conference Call and Webcast
Mar 13, 2023 08:35AM Moleculin to Present at the Oppenheimer 33rd Annual Healthcare Conference
Mar 13, 2023 07:05AM Moleculin Biotech (MBRX) Has No Exposure to Silicon Valley Bank Situation
Mar 13, 2023 07:05AM Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation
Mar 9, 2023 08:35AM Moleculin Biotech (MBRX) Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer
Mar 9, 2023 08:35AM Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer
Mar 1, 2023 08:45AM Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Feb 13, 2023 08:11AM Moleculin Biotech (MBRX) Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of R/R AML
Feb 13, 2023 08:10AM Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Jan 11, 2023 01:00PM JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th
Jan 5, 2023 08:45AM Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event
Dec 21, 2022 08:26AM Moleculin Biotech (MBRX) Approved in Italy for Phase 1/2 Trial of Annamycin in Combination with Cytarabine
Dec 21, 2022 08:25AM Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Dec 15, 2022 08:36AM Moleculin Biotech (MBRX) Reports 80% ORR in Phase 1 Trial of Annamycin
Dec 15, 2022 08:35AM Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)
Dec 7, 2022 08:46AM Moleculin Biotech (MBRX) Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Dec 7, 2022 08:45AM Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Nov 10, 2022 04:05PM Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
Nov 7, 2022 09:05AM Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast
Oct 14, 2022 08:40AM Moleculin Biotech (MBRX) Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Oct 14, 2022 08:40AM Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Sep 27, 2022 08:36AM Moleculin Biotech (MBRX) WP1096 Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral
Sep 27, 2022 08:35AM Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral
Sep 23, 2022 09:11AM Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event
Sep 8, 2022 08:45AM Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Sep 7, 2022 08:35AM Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 6, 2022 08:45AM Moleculin Biotech (MBRX) Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Sep 6, 2022 08:45AM Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Aug 19, 2022 08:40AM Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Aug 15, 2022 08:35AM Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update
Jul 28, 2022 08:35AM Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Jul 8, 2022 08:35AM Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
Jun 16, 2022 08:35AM Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK
May 26, 2022 08:35AM Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
May 19, 2022 08:05AM Moleculin to Present at the H.C. Wainwright Global Investment Conference
View More Recent Stories View Older Stories